Cell Biology 2020

Dr. Aguilar obtained his PhD degree in Immunochemistry from the School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina. Dr. Aguilar pursued his post-doctoral training at the National institutes of Health in Bethesda, MD in the lab of the well-known cell ... biologist Dr. Juan Bonifacino. In 2005, after a period as Associate Research Scientist at The Johns Hopkins University (in Dr. Beverly Wendland lab), Dr. Aguilar joined the Faculty of the Department of Biological Sciences at Purdue University. There, his group studies the mechanisms linking endocytosis and signaling in health and disease. In order to pursue its research goals, the Aguilar lab routinely use biophysical, biochemical and genetic approaches.

Matt entered the research field over 20 years ago as a lab animal technician at the TSI/Mason contract research facility. He has worked at both contract facilities such as TSI and OREAD Biosafety as well in industry at Pharmacia, Pfizer, and Sanofi-Aventis. During that period he ... has performed a variety of surgical procedures including device implantation, transplants, orthopedic defect, ocular and vascular implants, cardiac surgery, and brain and spinal procedures. His experience ranges from mice and rats to non-human primates and livestock. In addition, he holds four patents for novel surgical devices and implants and has been training technicians, scientists, veterinarians, and physicians in surgical techniques and procedures for over 15 years. Outside of the surgical realm, he has been a study director, sonographer, Safety Pharmacology scientist, and manager. Currently Matt supervises a team of technicians and surgeon-technicians at Genzyme who support the Boston hub and perform over 1250 surgical procedures a year. Matt was also on the board of directors for the Academy of Surgical Research for over ten years, serving as their program chair for three of them as well as educational chair for two. Currently he is the program chairman for the New England branch of AALAS.

Dr. Laura Perin is an Assistant Professor at the Keck School of Medicine, University of Southern California. Dr Perin obtained a master's degree in Biological Sciences at the University of Padova, Italy in 2000 and a Ph.D. in Stem cells and Tissue Engineering at the Harvard ... School of Medicine in 2004. Dr Perin completed her post-doc training at Children's Hospital Los Angeles/Keck School of Medicine in 2009. Dr. Perin's group studies the mechanisms that regulate kidney damage, with specific attention to glomerular injuries. She uses different regenerative approaches including extracellular vesicles, organ a chip technology, and development biology. Dr. Perin has received many intramural and extramural awards from different organizations, including the National Institute of Heath, and has published more than 40 articles in the field of renal regeneration.

Leading Novabiosis' primary cell business, Matthew brings to the Company a skill for implementing sales-driven business strategies, an extensive track record of meeting and surpassing targeted sales objectives, and a passion for translating customer needs into solutions that ... exceed customer expectations. In addition to his role of leading the Company's outreach and customer relationships; he very works closely with Novabiosis experienced R&D team to articulate market needs and identify opportunities for new products. Over the past fourteen years, Mr. Shipton has amassed deep domain expertise in cell-based products and services. Prior to joining Novabiosis, he served as Chief Operating Officer for Hurel Corp, overseeing Hurel's commercial operations. Before joining Hurel, Matthew served as the Central and Southern U.S. Regional Sales Manager for Bioreclamation IVT (formerly CelsisIVT), where he was responsible for leading regional revenue generation and new account growth. In that capacity Mr. Shipton organized and led multiple, dedicated strategic initiatives, including establishing the CelsisIVT partnership with the Research Institute for Liver Disease (RILD) in China, as well as consummating long-term supply agreements with a number of the major pharmaceutical companies. Prior to CelsisIVT, Mr. Shipton served as Director of North American Business Development for Cyprotex, PLC, a UK-based contract research organization ("CRO") specializing in preclinical drug discovery services. Before Cyprotex, he was Regional Sales Manager for CellzDirect, a Durham, NC based provider of primary hepatic cell-based products and services which in 2008 was acquired by Invitrogen (now Thermo Fisher). Mr. Shipton holds Master's and Bachelor's Degrees in Chemistry from, respectively, North Carolina State University and Youngstown State University.